---
title: "Repligen to buy BioLife Solutions for about USD 1.5 billion, offers USD 31 a share"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293454273.md"
description: "Repligen agreed to acquire BioLife Solutions for approximately $1.5 billion, offering $31 per share in a mix of 64% stock and 36% cash. The transaction is expected to close in Q4 2026, pending shareholder approval. Repligen projects at least $20 million in synergies in the first year and $30 million in the second year."
datetime: "2026-07-22T10:02:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293454273.md)
  - [en](https://longbridge.com/en/news/293454273.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293454273.md)
---

# Repligen to buy BioLife Solutions for about USD 1.5 billion, offers USD 31 a share

-   Repligen agreed to buy BioLife Solutions in a deal valuing the target at about $1.5 billion. \* BioLife holders to receive USD 11.25 cash plus 0.1442 Repligen shares per share, valued at USD 31. \* Consideration split: 64% stock, 36% cash; cash portion funded from cash on hand. \* Transaction expected to close in Q4 2026, subject to BioLife stockholder vote and customary conditions. \* Repligen projects at least USD 20 million synergies in year one, at least USD 30 million in year two. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Repligen Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607220600PRIMZONEFULLFEED9766145) on July 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [BLFS.US](https://longbridge.com/en/quote/BLFS.US.md)
- [RGEN.US](https://longbridge.com/en/quote/RGEN.US.md)

## Related News & Research

- [Repligen says BioLife deal targets Q4 close pending regulatory, shareholder approvals](https://longbridge.com/en/news/294739855.md)
- [Repligen–BioLife Deal: Market, Integration and Regulatory Risks Threaten Growth Outlook and Shareholder Returns](https://longbridge.com/en/news/294466535.md)
- [BioLife Solutions Q2 revenue rises 21% year over year](https://longbridge.com/en/news/295138582.md)
- [Aether Global Innovations Provides an Update on Previously Announced Acquisition of Arion](https://longbridge.com/en/news/294885583.md)
- [Tarsus to buy Alkeus in deal worth about $450 million upfront](https://longbridge.com/en/news/295097320.md)